HER2阳性晚期乳腺癌-话题@MedSci

#HER2阳性晚期乳腺癌#

18篇内容 | 810人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2162587, encodeId=817a216258e36, content=<a href='/topic/show?id=2cb21063650c' target=_blank style='color:#2F92EE;'>#达尔西利#</a>（Dalpiciclib）联合<a href='/topic/show?id=2a4d391818a' target=_blank style='color:#2F92EE;'>#吡咯替尼#</a>（pyrotinib）治疗<a href='/topic/show?id=cdde8e36f9' target=_blank style='color:#2F92EE;'>#HER2阳性晚期乳腺癌#</a><a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>, objectTitle=NAT COMMUN：达尔西利（Dalpiciclib）联合吡咯替尼（pyrotinib）治疗HER2阳性晚期乳腺癌的单臂II期临床试验, objectType=article, longId=795214, objectId=0cbce95214d8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301008/1696780084045_6145188.jpg, objectUrl=/article/show_article.do?id=0cbce95214d8, replyNumber=0, likeNumber=49, createdTime=2023-10-13, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0cbce95214d8, moduleTitle=NAT COMMUN：达尔西利（Dalpiciclib）联合吡咯替尼（pyrotinib）治疗HER2阳性晚期乳腺癌的单臂II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cbce95214d8)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1991730, encodeId=ee841991e303e, content=<a href='/topic/show?id=cdde8e36f9' target=_blank style='color:#2F92EE;'>#HER2阳性晚期乳腺癌#</a>, objectTitle=HER2阳性晚期乳腺癌治疗进展文献回顾, objectType=article, longId=736701, objectId=3186e367017a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3186e367017a, replyNumber=0, likeNumber=54, createdTime=2023-03-09, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3186e367017a, moduleTitle=HER2阳性晚期乳腺癌治疗进展文献回顾, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3186e367017a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991727, encodeId=c7761991e2793, content=<a href='/topic/show?id=cdde8e36f9' target=_blank style='color:#2F92EE;'>#HER2阳性晚期乳腺癌#</a>, objectTitle=ASCO指南重磅更新！对于HER2阳性晚期乳腺癌，最佳治疗到底是什么？最新最全循证依据也都在这了！, objectType=article, longId=728444, objectId=eacae28444f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eacae28444f5, replyNumber=0, likeNumber=67, createdTime=2023-05-10, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eacae28444f5, moduleTitle=ASCO指南重磅更新！对于HER2阳性晚期乳腺癌，最佳治疗到底是什么？最新最全循证依据也都在这了！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eacae28444f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991728, encodeId=57811991e28d1, content=<a href='/topic/show?id=cdde8e36f9' target=_blank style='color:#2F92EE;'>#HER2阳性晚期乳腺癌#</a>, objectTitle=ASCO指南又双叒有更新啦！HER2阳性晚期乳腺癌脑转移如何处理？一图看清！, objectType=article, longId=728535, objectId=b917e285354b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b917e285354b, replyNumber=0, likeNumber=62, createdTime=2022-11-26, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b917e285354b, moduleTitle=ASCO指南又双叒有更新啦！HER2阳性晚期乳腺癌脑转移如何处理？一图看清！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b917e285354b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991729, encodeId=64731991e29a9, content=<a href='/topic/show?id=cdde8e36f9' target=_blank style='color:#2F92EE;'>#HER2阳性晚期乳腺癌#</a>, objectTitle=王涛教授：HER2阳性晚期乳腺癌治疗进展, objectType=article, longId=736318, objectId=aac6e3631804, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aac6e3631804, replyNumber=0, likeNumber=58, createdTime=2023-05-25, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aac6e3631804, moduleTitle=王涛教授：HER2阳性晚期乳腺癌治疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aac6e3631804)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991726, encodeId=f1b31991e26bc, content=<a href='/topic/show?id=cdde8e36f9' target=_blank style='color:#2F92EE;'>#HER2阳性晚期乳腺癌#</a>, objectTitle=Clin Cancer Res：PATRICIA试验 | Palbociclib联合曲妥珠单抗治疗HER2阳性晚期乳腺癌, objectType=article, longId=203556, objectId=4991203556ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4991203556ab, replyNumber=0, likeNumber=60, createdTime=2021-03-19, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4991203556ab, moduleTitle=Clin Cancer Res：PATRICIA试验 | Palbociclib联合曲妥珠单抗治疗HER2阳性晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4991203556ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991724, encodeId=a9a21991e24ed, content=<a href='/topic/show?id=cdde8e36f9' target=_blank style='color:#2F92EE;'>#HER2阳性晚期乳腺癌#</a>, objectTitle=滕月娥教授：HER2阳性晚期乳腺癌治疗进展, objectType=article, longId=181940, objectId=d71d18194001, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d71d18194001, replyNumber=0, likeNumber=56, createdTime=2020-04-17, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d71d18194001, moduleTitle=滕月娥教授：HER2阳性晚期乳腺癌治疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d71d18194001)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991723, encodeId=f28b1991e232b, content=<a href='/topic/show?id=cdde8e36f9' target=_blank style='color:#2F92EE;'>#HER2阳性晚期乳腺癌#</a>, objectTitle=2019ESMO|细说HER2阳性晚期乳腺癌治疗那些事儿, objectType=article, longId=181202, objectId=825818120299, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=825818120299, replyNumber=0, likeNumber=59, createdTime=2020-05-22, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=825818120299, moduleTitle=2019ESMO|细说HER2阳性晚期乳腺癌治疗那些事儿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=825818120299)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991725, encodeId=b2f71991e2598, content=<a href='/topic/show?id=cdde8e36f9' target=_blank style='color:#2F92EE;'>#HER2阳性晚期乳腺癌#</a>, objectTitle=罗氏乳腺癌创新靶向药帕捷特®又一适应症在中国获批，开启HER2阳性晚期乳腺癌治疗新格局, objectType=article, longId=184654, objectId=946f18465458, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=946f18465458, replyNumber=0, likeNumber=66, createdTime=2020-09-30, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=946f18465458, moduleTitle=罗氏乳腺癌创新靶向药帕捷特®又一适应症在中国获批，开启HER2阳性晚期乳腺癌治疗新格局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=946f18465458)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991722, encodeId=cb021991e221d, content=<a href='/topic/show?id=cdde8e36f9' target=_blank style='color:#2F92EE;'>#HER2阳性晚期乳腺癌#</a>, objectTitle=闫敏教授：从证据到实践，吡咯替尼为HER2阳性晚期乳腺癌治疗带来哪些改变, objectType=article, longId=179296, objectId=961a1e92963d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=961a1e92963d, replyNumber=0, likeNumber=52, createdTime=2019-09-29, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=961a1e92963d, moduleTitle=闫敏教授：从证据到实践，吡咯替尼为HER2阳性晚期乳腺癌治疗带来哪些改变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=961a1e92963d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991720, encodeId=b1941991e20ea, content=<a href='/topic/show?id=cdde8e36f9' target=_blank style='color:#2F92EE;'>#HER2阳性晚期乳腺癌#</a>, objectTitle=HER2指南者说丨张清媛教授：从《2019 CSCO乳腺癌诊疗指南》更新要点看HER2阳性晚期乳腺癌治疗格局的改变, objectType=article, longId=165416, objectId=5e681654165a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e681654165a, replyNumber=0, likeNumber=50, createdTime=2019-10-17, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e681654165a, moduleTitle=HER2指南者说丨张清媛教授：从《2019 CSCO乳腺癌诊疗指南》更新要点看HER2阳性晚期乳腺癌治疗格局的改变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e681654165a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991721, encodeId=db501991e2129, content=<a href='/topic/show?id=cdde8e36f9' target=_blank style='color:#2F92EE;'>#HER2阳性晚期乳腺癌#</a>, objectTitle=SOPHIA初步结果开辟HER2阳性晚期乳腺癌治疗新途径, objectType=article, longId=168401, objectId=633a16840184, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=633a16840184, replyNumber=0, likeNumber=63, createdTime=2020-01-08, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=633a16840184, moduleTitle=SOPHIA初步结果开辟HER2阳性晚期乳腺癌治疗新途径, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=633a16840184)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991717, encodeId=852c1991e1711, content=<a href='/topic/show?id=cdde8e36f9' target=_blank style='color:#2F92EE;'>#HER2阳性晚期乳腺癌#</a>, objectTitle=吡咯替尼上市，带来HER2阳性晚期乳腺癌患者新选择新希望, objectType=article, longId=147830, objectId=b31f14e83085, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b31f14e83085, replyNumber=0, likeNumber=49, createdTime=2018-10-07, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b31f14e83085, moduleTitle=吡咯替尼上市，带来HER2阳性晚期乳腺癌患者新选择新希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b31f14e83085)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991719, encodeId=3dfa1991e1923, content=<a href='/topic/show?id=cdde8e36f9' target=_blank style='color:#2F92EE;'>#HER2阳性晚期乳腺癌#</a>, objectTitle=病例分享｜首诊IV期伴内脏转移HER2阳性晚期乳腺癌一例, objectType=article, longId=151957, objectId=fd5115195e0b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd5115195e0b, replyNumber=0, likeNumber=58, createdTime=2019-09-17, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd5115195e0b, moduleTitle=病例分享｜首诊IV期伴内脏转移HER2阳性晚期乳腺癌一例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd5115195e0b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991718, encodeId=f50f1991e1835, content=<a href='/topic/show?id=cdde8e36f9' target=_blank style='color:#2F92EE;'>#HER2阳性晚期乳腺癌#</a>, objectTitle=HER2阳性晚期乳腺癌伴脑转移一例, objectType=article, longId=149806, objectId=ef87149806e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef87149806e1, replyNumber=0, likeNumber=61, createdTime=2019-04-17, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef87149806e1, moduleTitle=HER2阳性晚期乳腺癌伴脑转移一例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef87149806e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991715, encodeId=92a91991e155b, content=<a href='/topic/show?id=cdde8e36f9' target=_blank style='color:#2F92EE;'>#HER2阳性晚期乳腺癌#</a>, objectTitle=[ABC4圆桌会] HER2阳性晚期乳腺癌：以抗HER2为基础，从一线到维持治疗, objectType=article, longId=119835, objectId=da0c1198353d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da0c1198353d, replyNumber=0, likeNumber=56, createdTime=2017-11-14, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da0c1198353d, moduleTitle=[ABC4圆桌会] HER2阳性晚期乳腺癌：以抗HER2为基础，从一线到维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da0c1198353d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991716, encodeId=44af1991e1635, content=<a href='/topic/show?id=cdde8e36f9' target=_blank style='color:#2F92EE;'>#HER2阳性晚期乳腺癌#</a>, objectTitle=EUR J Cancer： buparlisib联合拉帕替尼治疗曲妥珠单抗拮抗的HER2阳性晚期乳腺癌, objectType=article, longId=124477, objectId=e6f71244e794, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6f71244e794, replyNumber=0, likeNumber=58, createdTime=2018-02-20, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6f71244e794, moduleTitle=EUR J Cancer： buparlisib联合拉帕替尼治疗曲妥珠单抗拮抗的HER2阳性晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6f71244e794)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1991714, encodeId=b3371991e143a, content=<a href='/topic/show?id=cdde8e36f9' target=_blank style='color:#2F92EE;'>#HER2阳性晚期乳腺癌#</a>, objectTitle=[ABC4]徐兵河教授：HER2阳性晚期乳腺癌治疗的“变”与“不变”, objectType=article, longId=119222, objectId=de27119222d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de27119222d0, replyNumber=0, likeNumber=55, createdTime=2018-04-09, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de27119222d0, moduleTitle=[ABC4]徐兵河教授：HER2阳性晚期乳腺癌治疗的“变”与“不变”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de27119222d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HER2阳性晚期乳腺癌

2020-05-29

(审核中...)

前往app查看评论内容

#达尔西利#（Dalpiciclib）联合#吡咯替尼#（pyrotinib）治疗#HER2阳性晚期乳腺癌##乳腺癌#

NAT COMMUN：达尔西利（Dalpiciclib）联合吡咯替尼（pyrotinib）治疗HER2阳性晚期乳腺癌的单臂II期临床试验

2023-10-13发表于上海

juliusluan78 (审核中...)

前往app查看评论内容

#HER2阳性晚期乳腺癌#

HER2阳性晚期乳腺癌治疗进展文献回顾

2023-03-09

juliusluan78 (审核中...)

前往app查看评论内容

#HER2阳性晚期乳腺癌#

ASCO指南重磅更新！对于HER2阳性晚期乳腺癌，最佳治疗到底是什么？最新最全循证依据也都在这了！

2023-05-10

juliusluan78 (审核中...)

前往app查看评论内容

#HER2阳性晚期乳腺癌#

ASCO指南又双叒有更新啦！HER2阳性晚期乳腺癌脑转移如何处理？一图看清！

2022-11-26

juliusluan78 (审核中...)

前往app查看评论内容

#HER2阳性晚期乳腺癌#

王涛教授：HER2阳性晚期乳腺癌治疗进展

2023-05-25

juliusluan78 (审核中...)

前往app查看评论内容

#HER2阳性晚期乳腺癌#

Clin Cancer Res：PATRICIA试验 | Palbociclib联合曲妥珠单抗治疗HER2阳性晚期乳腺癌

2021-03-19

juliusluan78 (审核中...)

前往app查看评论内容

#HER2阳性晚期乳腺癌#

滕月娥教授：HER2阳性晚期乳腺癌治疗进展

2020-04-17

juliusluan78 (审核中...)

前往app查看评论内容

#HER2阳性晚期乳腺癌#

2019ESMO|细说HER2阳性晚期乳腺癌治疗那些事儿

2020-05-22

juliusluan78 (审核中...)

前往app查看评论内容

#HER2阳性晚期乳腺癌#

罗氏乳腺癌创新靶向药帕捷特®又一适应症在中国获批，开启HER2阳性晚期乳腺癌治疗新格局

2020-09-30

juliusluan78 (审核中...)

前往app查看评论内容

#HER2阳性晚期乳腺癌#

闫敏教授：从证据到实践，吡咯替尼为HER2阳性晚期乳腺癌治疗带来哪些改变

2019-09-29

juliusluan78 (审核中...)

前往app查看评论内容

#HER2阳性晚期乳腺癌#

HER2指南者说丨张清媛教授：从《2019 CSCO乳腺癌诊疗指南》更新要点看HER2阳性晚期乳腺癌治疗格局的改变

2019-10-17

juliusluan78 (审核中...)

前往app查看评论内容

#HER2阳性晚期乳腺癌#

SOPHIA初步结果开辟HER2阳性晚期乳腺癌治疗新途径

2020-01-08

juliusluan78 (审核中...)

前往app查看评论内容

#HER2阳性晚期乳腺癌#

吡咯替尼上市，带来HER2阳性晚期乳腺癌患者新选择新希望

2018-10-07

juliusluan78 (审核中...)

前往app查看评论内容

#HER2阳性晚期乳腺癌#

病例分享｜首诊IV期伴内脏转移HER2阳性晚期乳腺癌一例

2019-09-17

juliusluan78 (审核中...)

前往app查看评论内容

#HER2阳性晚期乳腺癌#

HER2阳性晚期乳腺癌伴脑转移一例

2019-04-17

juliusluan78 (审核中...)

前往app查看评论内容

#HER2阳性晚期乳腺癌#

[ABC4圆桌会] HER2阳性晚期乳腺癌：以抗HER2为基础，从一线到维持治疗

2017-11-14

juliusluan78 (审核中...)

前往app查看评论内容

#HER2阳性晚期乳腺癌#

EUR J Cancer： buparlisib联合拉帕替尼治疗曲妥珠单抗拮抗的HER2阳性晚期乳腺癌

2018-02-20

juliusluan78 (审核中...)

前往app查看评论内容

#HER2阳性晚期乳腺癌#

[ABC4]徐兵河教授：HER2阳性晚期乳腺癌治疗的“变”与“不变”

2018-04-09

科室
- - 订阅+
  - 更多科室
工具
服务